Successful treatment with sofosbuvir and daclatasvir plus ribavirin in acute hepatitis C-infected patient with hepatic decompensation

被引：1

作者：

Wu, Sih-Hsien ^{[1
]}

Chao, Chi-Jen ^{[1
,2
]}

Huang, Yi-Hsiang ^{[1
,2
]}

Hou, Ming-Chih ^{[1
,2
]}

机构：

[1] Taipei Vet Gen Hosp, Dept Med, Div Gastroenterol & Hepatol, 201 Sect 2,Shih Pai Rd, Taipei 112, Taiwan

[2] Natl Yang Ming Univ, Sch Med, Fac Med, Taipei, Taiwan

来源：

JOURNAL OF THE CHINESE MEDICAL ASSOCIATION | 2019年 / 82卷 / 07期

关键词：

Acute hepatitis C; Direct acting antiviral agent; Hepatic decompensation; VIRUS GENOTYPE 1; B-VIRUS; ASIAN PATIENTS; HCV INFECTION; SINGLE-ARM; OPEN-LABEL; LEDIPASVIR; SUPERINFECTION; EPIDEMIOLOGY; INDIVIDUALS;

D O I：

10.1097/JCMA.0000000000000107

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Treatment of chronic hepatitis C virus infection has evolved rapidly in recent years due to the invention of interferon-free direct antiviral agents (DAAs). However, evidence and recommendations for acute hepatitis C (AHC) virus infection by DAAs are still limited, especially for those whose disease presents with hepatic decompensation. Here, we report a case with genotype 1b AHC virus infection, complicated by hepatic decompensation and the patient received sofosbuvir and daclatasvir plus low dose ribavirin for 12 weeks. Serum hepatitis C virus RNA significantly declines after therapy and became undetectable at week 8 and it remained undetectable at 12 weeks after finishing therapy; sustained virological response was impressed. Our findings support that combination of sofosbuvir and daclatasvir plus ribavirin can be used for genotype 1b, AHC virus infection patients with overt hepatic decompensation.

引用

页码：595 / 598

页数：4

共 28 条

[1] Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease [J].

Charlton, Michael ;

Everson, Gregory T. ;

Flamm, Steven L. ;

Kumar, Princy ;

Landis, Charles ;

Brown, Robert S., Jr. ;

Fried, Michael W. ;

Terrault, Norah A. ;

O'Leary, Jacqueline G. ;

Vargas, Hugo E. ;

Kuo, Alexander ;

Schiff, Eugene ;

Sulkowski, Mark S. ;

Gilroy, Richard ;

Watt, Kymberly D. ;

Brown, Kimberly ;

Kwo, Paul ;

Pungpapong, Surakit ;

Korenblat, Kevin M. ;

Muir, Andrew J. ;

Teperman, Lewis ;

Fontana, Robert J. ;

Denning, Jill ;

Arterburn, Sarah ;

Dvory-Sobol, Hadas ;

Brandt-Sarif, Theo ;

Pang, Phillip S. ;

McHutchison, John G. ;

Reddy, K. Rajender ;

Afdhal, Nezam .

GASTROENTEROLOGY, 2015, 149 (03) :649-659

[2] Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus [J].

Chung, Raymond T. ;

Davis, Gary L. ;

Jensen, Donald M. ;

Masur, Henry ;

Saag, Michael S. ;

Thomas, David L. ;

Aronsohn, Andrew I. ;

Charlton, Michael R. ;

Feld, Jordan J. ;

Fontana, Robert J. ;

Ghany, Marc G. ;

Godofsky, Eliot W. ;

Graham, Camilla S. ;

Kim, Arthur Y. ;

Kiser, Jennifer J. ;

Kottilil, Shyam ;

Marks, Kristen M. ;

Martin, Paul ;

Mitruka, Kiren ;

Morgan, Timothy R. ;

Naggie, Susanna ;

Raymond, Daniel ;

Reau, Nancy S. ;

Schooley, Robert T. ;

Sherman, Kenneth E. ;

Sulkowski, Mark S. ;

Vargas, Hugo E. ;

Ward, John W. ;

Wyles, David L. .

HEPATOLOGY, 2015, 62 (03) :932-954

[3] Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis [J].

Curry, M. P. ;

O'Leary, J. G. ;

Bzowej, N. ;

Muir, A. J. ;

Korenblat, K. M. ;

Fenkel, J. M. ;

Reddy, K. R. ;

Lawitz, E. ;

Flamm, S. L. ;

Schiano, T. ;

Teperman, L. ;

Fontana, R. ;

Schiff, E. ;

Fried, M. ;

Doehle, B. ;

An, D. ;

McNally, J. ;

Osinusi, A. ;

Brainard, D. M. ;

McHutchison, J. G. ;

Brown, R. S., Jr. ;

Charlton, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (27) :2618-2628

[4] Projecting future complications of chronic hepatitis C in the United States [J].

Davis, GL ;

Albright, JE ;

Cook, SF ;

Rosenberg, DM .

LIVER TRANSPLANTATION, 2003, 9 (04) :331-338

[5] Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study [J].

Deterding, Katja ;

Spinner, Christoph D. ;

Schott, Eckart ;

Welzel, Tania M. ;

Gerken, Guido ;

Klinker, Hartwig ;

Spengler, Ulrich ;

Wiegand, Johannes ;

zur Wiesch, Julian Schulze ;

Pathil, Anita ;

Cornberg, Markus ;

Umgelter, Andreas ;

Zoellner, Caroline ;

Zeuzem, Stefan ;

Papkalla, Armin ;

Weber, Kristina ;

Hardtke, Svenja ;

von der Leyen, Heiko ;

Koch, Armin ;

von Witzendorff, Dorothee ;

Manns, Michael P. ;

Wedemeyer, Heiner .

LANCET INFECTIOUS DISEASES, 2017, 17 (02) :215-222

[6] Sofosbuvir in the treatment of early HCV infection in HIV-infected men [J].

El Sayed, Ahmed ;

Barbati, Zachary R. ;

Turner, Samuel S. ;

Foster, Andrew L. ;

Morey, Tristan ;

Dieterich, Douglas T. ;

Fierer, Daniel S. .

HIV CLINICAL TRIALS, 2017, 18 (02) :60-66

[7] EASL Recommendations on Treatment of Hepatitis C 2016 [J].

European Association for the Study of the Liver easloffice@easloffice.eu .

JOURNAL OF HEPATOLOGY, 2017, 66 (01) :153-194

[8] Global epidemiology and genotype distribution of the hepatitis C virus infection [J].

Gower, Erin ;

Estes, Chris ;

Blach, Sarah ;

Razavi-Shearer, Kathryn ;

Razavi, Homie .

JOURNAL OF HEPATOLOGY, 2014, 61 :S45-S57

[9] A smouldering public-health crisis [J].

Gravitz, Lauren .

NATURE, 2011, 474 (7350) :S2-S4

[10] Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence [J].

Hanafiah, Khayriyyah Mohd ;

Groeger, Justina ;

Flaxman, Abraham D. ;

Wiersma, Steven T. .

HEPATOLOGY, 2013, 57 (04) :1333-1342

← 1 2 3 →